Fund Basics
See More- Fund Family Ark Funds
- Assets Under Management 19,221,100
- Shares Outstanding, K 230
- 60-Month Beta N/A
- Price/Earnings ttm N/A
- Annual Dividend & Yield 0.00 (0.00%)
- Most Recent Dividend N/A on N/A
- Management Fee 0.21%
Ark 21Shares Bitcoin ETF (ARKB)
83.52 x 1 84.25 x 1
Post-market by (Cboe BZX)
83.57 -3.27 (-3.77%) 03/28/25 [NYSE Arca]
83.52 x 1 84.25 x 1
Post-market 84.24 +0.67 (+0.80%) 17:56 ET
for Fri, Mar 28th, 2025
Day Low
83.30
Day High
85.33
Open 85.06
Previous Close 86.84 86.84
Volume 672,161 672,161
Avg Vol 992,873 992,873
Stochastic %K 66.53% 66.53%
Weighted Alpha +23.00 +23.00
5-Day Change -0.15 (-0.19%) -0.15 (-0.19%)
52-Week Range 49.53 - 108.28 49.53 - 108.28
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
-
OHLC Bars
-
Colored OHLC Bars
-
HLC Bars
-
Candlestick Hollow
-
Candlestick Open-to-Close
-
Candlestick Close-to-Close
-
Heikin-Ashi
-
Line Chart
-
Area Chart
-
Renko
-
Column
-
Baseline
-
Line Break
-
Range
-
Kagi
-
Point And Figure
Realtime quote and/or trades are not sourced from all markets.
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.
Most Recent Stories
More News
Bitcoin leads the crypto pack. Its influence extends beyond the coin itself and now like other assets, Bitcoin also has a derivatives market. A new trend is emerging: Bitcoin ETF options, and these...
Despite a volatile start to the year, the optimism surrounding Bitcoin has still not wavered. After surging about 111% in 2024, the digital asset experienced fluctuations at the beginning of this year....
The demand for Bitcoin ETFs is showing no signs of slowdown despite the tariff turmoil. This is especially true as Bitcoin ETFs collectively pulled in $1.1 billion in the five trading days ending Tuesday,...
After experiencing a volatile start to the year, Bitcoin seems to be back on track for a blockbuster year ahead. The digital currency fell roughly 9.5% for three days starting Jan. 5 but has since then...
Could XRP (Ripple) Make You a Millionaire in 2025?
Many investors dream of making millions in financial markets. And for many, the cryptocurrency industry has helped turn that vision into a reality. The Ripple network's native token XRP (CRYPTO: XRP) is...
Billionaires Are Selling Nvidia and Buying a Bitcoin ETF That Cathie Wood Thinks Could Soar Up to 3,700%
Some big institutional investors are pivoting from the AI chipmaker toward the world's top cryptocurrency.
The cryptocurrency market is off to a wobbly start in the year 2025, weighed down by speculation that the Fed may have limited scope for further interest rate cuts. Bitcoin briefly fell below $90,000 on...
Does Robert Kiyosaki's Bullish 2025 Bitcoin Prediction Make Sense?
Check out how the "Rich Dad Poor Dad" author's generous price targets align with Bitcoin's active catalysts.
1 Top Cryptocurrency to Buy Before It Soars 1,477%, According to Cathie Wood
Cathie Wood is closely watched by many investors. Her firm, Ark Invest, focuses on innovative and disruptive companies it believes can register tremendous growth. The hope is that this results in strong...
The ARK Next Generation Internet ETF (ARKW) is a prime investment opportunity for 2025 with a crypto- and tech-heavy portfolio.
There are Positive Developments in the Treatment of Metastatic Breast Cancer
A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...
Five Impressive Metastatic Cancer Treatment Stocks to Own Today
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the first...
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023...
Positive Developments for Breast Cancer Care Attracting Big Investor Attention
A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 8, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December...
There are Positive Developments in the Treatment of Metastatic Breast Cancer
A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...
Five Impressive Metastatic Cancer Treatment Stocks to Own Today
A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the first...
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023...
Positive Developments for Breast Cancer Care Attracting Big Investor Attention
A significant medical breakthrough is sorely needed in the fight against breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of invasive...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 8, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted...
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant...
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the fourth quarter and year ended December...